Based on international guidelines PSMA PET/CT is recommended in initial staging in high- and intermediate-risk prostate cancer patients, in evaluation of localization of biochemical recurrent and biochemical persistent prostate cancer, localization of prostate cancer which is non-metastatic according to conventional imaging (metastatic castration-resistant prostate cancer), and staging before PSMA-directed radioligand therapy [3]. This evidence concerns the gene FOLH1 and prostate cancer.